Mast Accelerates Enrollment In Pivotal Sickle Cell Study Of MST-188
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With enrollment finally ramping up in trial open to older patients, Mast Therapeutics envisions a broad labeling horizon for MST-188, after a very long development road.